$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000162828021003060 Filed on February 24, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$50.03M	$50.12M	$29.00K
YoY Change	172417.24%	15660.38%	-3.33%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$50.12M
YoY Change		15660.38%
Gross Profit Margin		100.0%
Selling, General & Admin	$95.98M	$96.00M	$7.250M
YoY Change	1223.9%	330.49%	107.14%
% of Gross Profit		191.55%
Research & Development	$13.17M	$50.30M	$13.29M
YoY Change	-0.9%	-4.91%	22.6%
% of Gross Profit		100.36%
Depreciation & Amortization	$410.0K	$82.00K	$390.0K
YoY Change	5.13%	148.48%	8.33%
% of Gross Profit		0.16%
Operating Expenses	$58.08M	$154.4M	$34.87M
YoY Change	66.57%	69.19%	137.37%
Operating Profit	-$8.052M	-$104.3M	-$34.84M
YoY Change	-76.89%	14.68%
Interest Expense	$1.516M	$1.516M	-$47.53M
YoY Change	-103.19%	-43.89%	-34050.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$102.8M	-$102.8M	-$76.39M
YoY Change	34.54%	16.47%	426.1%
Income Tax	-$94.00K	-$94.00K	$90.00K
% Of Pretax Income
Net Earnings	-$8.074M	-$102.7M	-$34.46M
YoY Change	-76.57%	16.17%	136.18%
Net Earnings / Revenue	-16.14%	-204.88%	-118824.14%
Basic Earnings Per Share	-$0.06	-$0.87
Diluted Earnings Per Share	-$0.06	-$0.87	-$0.78
COMMON SHARES
Basic Shares Outstanding		118.5M shares
Diluted Shares Outstanding		118.5M shares

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$398.3M	$398.3M	$306.0M
YoY Change	30.17%	30.16%	143.05%
Cash & Equivalents	$272.4M	$272.4M	$306.0M
Short-Term Investments	$126.0M	$126.0M	$0.00
Other Short-Term Assets	$1.018M	$6.153M	$8.800M
YoY Change	-88.43%	-29.68%	29.41%
Inventory	$13.93M	$13.93M	$0.00
Prepaid Expenses	$7.171M		$8.750M
Receivables	$486.0K	$486.0K	$400.0K
Other Receivables	$51.00K	$532.0K	$163.0K
Total Short-Term Assets	$419.4M	$419.4M	$315.1M
YoY Change	33.09%	33.09%	137.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.786M	$10.28M	$93.00K
YoY Change	5046.24%	10948.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$24.38M	$24.38M
YoY Change
Other Assets	$247.0K	$247.0K	$209.0K
YoY Change	18.18%	18.18%	-47.75%
Total Long-Term Assets	$44.23M	$44.23M	$9.164M
YoY Change	382.69%	382.69%	-30.05%
TOTAL ASSETS
Total Short-Term Assets	$419.4M	$419.4M	$315.1M
Total Long-Term Assets	$44.23M	$44.23M	$9.164M
Total Assets	$463.7M	$463.7M	$324.3M
YoY Change	42.97%	42.97%	122.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.80M	$2.635M	$11.20M
YoY Change	121.43%	-36.55%	57.75%
Accrued Expenses	$788.0K	$22.95M
YoY Change		226.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$32.00M	$32.00M	$11.30M
YoY Change	183.28%	183.28%	54.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$16.30M	$23.91M	$6.206M
YoY Change	162.65%	66.0%	-76.13%
Total Long-Term Liabilities	$16.30M	$23.91M	$6.206M
YoY Change	162.65%	66.0%	-76.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.00M	$32.00M	$11.30M
Total Long-Term Liabilities	$16.30M	$23.91M	$6.206M
Total Liabilities	$55.91M	$55.91M	$25.70M
YoY Change	117.54%	117.54%	-22.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$575.2M		-$472.5M
YoY Change	21.73%
Common Stock	$39.38M		$25.39M
YoY Change	55.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$407.8M	$407.8M	$298.6M
YoY Change
Total Liabilities & Shareholders Equity	$463.7M	$463.7M	$324.3M
YoY Change	42.97%	42.97%	122.28%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$8.074M	-$102.7M	-$34.46M
YoY Change	-76.57%	16.17%	136.18%
Depreciation, Depletion And Amortization	$410.0K	$82.00K	$390.0K
YoY Change	5.13%	148.48%	8.33%
Cash From Operating Activities	$3.204M	-$69.86M	-$25.28M
YoY Change	-112.67%	9.87%	85.75%
INVESTING ACTIVITIES
Capital Expenditures	-$2.183M	-$7.343M	$30.00K
YoY Change	-7376.67%	7170.3%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$21.33M	-$150.8M	$0.00
YoY Change		-2013.28%	-100.0%
Cash From Investing Activities	$19.15M	-$158.2M	-$30.00K
YoY Change	-63920.0%	-2132.46%	-100.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$187.7M
YoY Change		-15.86%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.242M	$194.4M	196.8M
YoY Change	-99.37%	-20.29%	32160.66%
NET CHANGE
Cash From Operating Activities	3.204M	-$69.86M	-25.28M
Cash From Investing Activities	19.15M	-$158.2M	-30.00K
Cash From Financing Activities	1.242M	$194.4M	196.8M
Net Change In Cash	23.59M	-$33.67M	171.5M
YoY Change	-86.24%	-117.9%	5485.67%
FREE CASH FLOW
Cash From Operating Activities	$3.204M	-$69.86M	-$25.28M
Capital Expenditures	-$2.183M	-$7.343M	$30.00K
Free Cash Flow	$5.387M	-$62.52M	-$25.31M
YoY Change	-121.28%	-1.53%	85.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:AssetsAbstract
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36421
CY2020	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4129078
CY2020	dei	City Area Code CityAreaCode	(250)
CY2020	dei	Local Phone Number LocalPhoneNumber	708-4272
CY2020	dei	Security12b Title Security12bTitle	Common shares, no par value
CY2020	dei	Trading Symbol TradingSymbol	AUPH
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q4	dei	Entity Public Float EntityPublicFloat	1740000000	USD
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	127450815	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272350000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	306019000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2019Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1018000	USD
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	368000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6153000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8750000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	419427000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	315137000	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24380000	USD
CY2019Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	247000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	209000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	93000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8862000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Assets Assets	463661000	USD
CY2019Q4	us-gaap	Assets Assets	324301000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11177000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	6000000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6118000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	118000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2020Q4	auph	Royalty Obligation Current RoyaltyObligationCurrent	294000	USD
CY2019Q4	auph	Royalty Obligation Current RoyaltyObligationCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31997000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11295000	USD
CY2019Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	6000000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1589000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6206000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	auph	Royalty Obligations Noncurrent RoyaltyObligationsNoncurrent	14706000	USD
CY2019Q4	auph	Royalty Obligations Noncurrent RoyaltyObligationsNoncurrent	8200000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	55911000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	25701000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126725000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126725000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111798000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111798000	shares
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	944328000	USD
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	746487000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	39383000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	25394000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-805000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-805000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575156000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-472476000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	298600000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463661000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	324301000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50118000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	463000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50327000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52866000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41382000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	95983000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22338000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13694000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1289000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1138000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1293000	USD
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	6809000	USD
CY2019	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	14919000	USD
CY2018	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-666000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	154408000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	91261000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	55703000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-104290000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-90943000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-55240000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	1516000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	2702000	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	2234000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102774000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88241000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53006000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	73000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.95
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118473000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93024000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84782000	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	177922000	USD
CY2018	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3071000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	943000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6860000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	135717000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	236747000	USD
CY2019	auph	Share Issuance Costs ShareIssuanceCosts	13629000	USD
CY2019	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	6988000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13748000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7414000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	298600000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000000	USD
CY2020	auph	Share Issuance Costs ShareIssuanceCosts	12268000	USD
CY2020	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6643000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	17454000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
CY2020	us-gaap	Depreciation Depreciation	82000	USD
CY2019	us-gaap	Depreciation Depreciation	33000	USD
CY2018	us-gaap	Depreciation Depreciation	20000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1289000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1138000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1293000	USD
CY2020	auph	Royalty Obligation Expense RoyaltyObligationExpense	6800000	USD
CY2019	auph	Royalty Obligation Expense RoyaltyObligationExpense	8200000	USD
CY2018	auph	Royalty Obligation Expense RoyaltyObligationExpense	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	17454000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	7414000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6860000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2677000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5986000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	706000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	650000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	151000	USD
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	108000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13927000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2559000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1826000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5004000	USD
CY2020	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	5489000	USD
CY2019	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2018	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13620000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4006000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-887000	USD
CY2020	auph	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	8407000	USD
CY2019	auph	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2018	auph	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69858000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63585000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51611000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	52108000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7884000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	36093000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	202951000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	36084000	USD
CY2020	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	5584000	USD
CY2019	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	85000	USD
CY2018	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	74000	USD
CY2020	us-gaap	Payments For Software PaymentsForSoftware	1675000	USD
CY2019	us-gaap	Payments For Software PaymentsForSoftware	0	USD
CY2018	us-gaap	Payments For Software PaymentsForSoftware	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	84000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-158186000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7783000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	187732000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	223118000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6642000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13748000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	943000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6988000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3071000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	194375000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	243854000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4014000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33669000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	188052000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-47662000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117967000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165629000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117967000	USD
CY2020	auph	Legal Settlements Paid LegalSettlementsPaid	0	USD
CY2019	auph	Legal Settlements Paid LegalSettlementsPaid	100000	USD
CY2018	auph	Legal Settlements Paid LegalSettlementsPaid	0	USD
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1884000	USD
CY2019	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2619000	USD
CY2018	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	2148000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	261000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	59000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of credit risk: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents and short term investments. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in US dollars and the majority of its expenses, including clinical trial costs are also denominated in US dollars, which mitigates the risk of material foreign exchange fluctuations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently anticipates to have 3 main customers and 1 rest of world partner for sales of LUPKYNIS. The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established when it is probable they will not be collected. Global economic conditions and customer-specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span></div>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272400000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2018	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50300000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52900000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41400000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13900000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	126000000.0	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24400000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2019Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	0	USD
CY2020Q4	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	150359000	USD
CY2019Q4	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	0	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	150359000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	422709000	USD
CY2019Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	0	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	306019000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	51000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	163000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	486000	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	205000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	481000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1018000	USD
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	368000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4965000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	250000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	250000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	179000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	157000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	7000000.0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	93000	USD
CY2020	us-gaap	Depreciation Depreciation	82000	USD
CY2019	us-gaap	Depreciation Depreciation	33000	USD
CY2018	us-gaap	Depreciation Depreciation	20000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18452000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9120000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2019	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16694000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7832000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8862000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	7000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	7000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	7000000.0	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	7000000.0	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2635000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4153000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10855000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3281000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11307000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3743000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11177000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-88694000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-53290000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50118000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	318000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	463000	USD
CY2020Q4	us-gaap	Noncurrent Assets NoncurrentAssets	4786000	USD
CY2019Q4	us-gaap	Noncurrent Assets NoncurrentAssets	93000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61024000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41750000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	453000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	284000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-102774000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88241000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53006000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	144000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	73000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-94000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.270
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	144000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	73000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	73000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.254
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.268
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.254
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.270
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Foreign EffectiveIncomeTaxRateReconciliationTaxCreditsForeign	-0.024
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.061
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.045
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.035
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.260
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.223
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.230
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	80087000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	56533000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6295000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4734000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2718000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1710000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4808000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3938000	USD
CY2020Q4	auph	Deferred Tax Assets Royalty Obligation DeferredTaxAssetsRoyaltyObligation	4006000	USD
CY2020	auph	Contractual Obligation Discount Rate ContractualObligationDiscountRate	0.103
CY2019Q4	auph	Deferred Tax Assets Royalty Obligation DeferredTaxAssetsRoyaltyObligation	2005000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5243000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2553000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	103157000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71473000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	101792000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	71459000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1365000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1173000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	192000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	14000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1365000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30300000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	307800000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	2233000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	65000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	2298000	USD
CY2020Q4	auph	Royalty Obligations RoyaltyObligations	15000000	USD
CY2019Q4	auph	Royalty Obligations RoyaltyObligations	8200000	USD
CY2019	auph	Contractual Obligation Discount Rate ContractualObligationDiscountRate	0.120
CY2020	auph	Royalty Obligations Period Increase Decrease RoyaltyObligationsPeriodIncreaseDecrease	6800000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P11Y
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2020Q4	auph	Lessee Operating Lease Number Of Extension Options LesseeOperatingLeaseNumberOfExtensionOptions	2	extension_option
CY2020Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P11Y
CY2020	auph	Lessee Operating Lease Lease Termination Term LesseeOperatingLeaseLeaseTerminationTerm	P7Y
CY2020	us-gaap	Lease Cost LeaseCost	944000	USD
CY2019	us-gaap	Lease Cost LeaseCost	297000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5500000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8400000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2020Q4	auph	Lease Right Of Use Asset LeaseRightOfUseAsset	5489000	USD
CY2019Q4	auph	Lease Right Of Use Asset LeaseRightOfUseAsset	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2018	us-gaap	Operating Lease Payments OperatingLeasePayments	151000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8407000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y8M1D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	909000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	229000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	35000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	68000	USD
CY2020	us-gaap	Lease Cost LeaseCost	944000	USD
CY2019	us-gaap	Lease Cost LeaseCost	297000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	232000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	114000	USD
CY2020	us-gaap	Short Term Lease Payments ShortTermLeasePayments	35000	USD
CY2019	us-gaap	Short Term Lease Payments ShortTermLeasePayments	68000	USD
CY2018	us-gaap	Short Term Lease Payments ShortTermLeasePayments	72000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	287000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	968000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1061000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1085000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1109000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6773000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11283000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2876000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8407000	USD
CY2020Q4	auph	Lessee Operating Lease Lease Not Yet Commenced Liability LesseeOperatingLeaseLeaseNotYetCommencedLiability	94000000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5063000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111800000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111800000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	85500000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	85500000	shares
CY2018Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	15000000.0	USD
CY2018Q4	auph	Sale Of Stock Weighted Average Price Per Share SaleOfStockWeightedAveragePricePerShare	6.51
CY2020	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	573143000	USD
CY2019	auph	Proceeds From Issuance Or Sale Of Equity Used To Date Net ProceedsFromIssuanceOrSaleOfEquityUsedToDateNet	249706000	USD
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111800000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111800000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	15800000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	14000000.0	shares
CY2020	auph	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStock	0.094
CY2019	auph	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStock	0.055
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4864000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.87
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3003000	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.29
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	276000	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.53
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7591000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.44
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M1D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18076000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2520000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.00
CY2019	auph	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Inducements ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossInducements	1600000	shares
CY2019	auph	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Inducement Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodInducementWeightedAverageExercisePrice	6.28
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3578000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.03
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	311000	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.40
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7822000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.47
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M20D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115655000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7568000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15610
CY2020	auph	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Inducements ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossInducements	925000	shares
CY2020	auph	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Inducement Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodInducementWeightedAverageExercisePrice	14360
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1593000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4390
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	236000	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11820
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14486000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11350
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M3D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35891000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3246000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.03
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.94
CY2020Q4	auph	Share Based Compensation Arrangement By Share Based Payment Award Number Of New Employees ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees	9	employee
CY2020Q3	auph	Share Based Compensation Arrangement By Share Based Payment Award Number Of New Employees ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNewEmployees	105	employee
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-88385000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.52
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.52
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.55
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0055
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0161
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0204
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.58
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.56
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.33
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14900000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	8500000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	10700000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	51500000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17500000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7400000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6900000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17454000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7414000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6860000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-102680000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118473000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93024000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84782000	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.95
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	26892000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16176000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9513000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12852000	shares
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50030000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	27090000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	42344000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	58082000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27060000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26863000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42315000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-8052000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-25932000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26544000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-42130000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-8074000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	230000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	14921000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	17172000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	24298000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	34870000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14891000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17143000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24068000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-34841000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14097000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-16375000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-23454000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-34459000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36

Files In Submission

Name	View Source	Status
0001628280-21-003060-index-headers.html	Edgar Link	pending
0001628280-21-003060-index.html	Edgar Link	pending
0001628280-21-003060.txt	Edgar Link	pending
0001628280-21-003060-xbrl.zip	Edgar Link	pending
articlespage11.jpg	Edgar Link	pending
articlespage21.jpg	Edgar Link	pending
articlespage31.jpg	Edgar Link	pending
articlespage41.jpg	Edgar Link	pending
auph-20201231.htm	Edgar Link	pending
auph-20201231.xsd	Edgar Link	pending
auph-20201231_cal.xml	Edgar Link	unprocessable
auph-20201231_def.xml	Edgar Link	unprocessable
auph-20201231_g1.jpg	Edgar Link	pending
auph-20201231_g2.jpg	Edgar Link	pending
auph-20201231_g3.jpg	Edgar Link	pending
auph-20201231_g4.jpg	Edgar Link	pending
auph-20201231_htm.xml	Edgar Link	completed
auph-20201231_lab.xml	Edgar Link	unprocessable
auph-20201231_pre.xml	Edgar Link	unprocessable
aurinalogo1.jpg	Edgar Link	pending
commonsharescertpg11.jpg	Edgar Link	pending
commonsharescertpg21.jpg	Edgar Link	pending
exhibit1010iljindefinitive.htm	Edgar Link	pending
exhibit1011employmentagree.htm	Edgar Link	pending
exhibit1012employmentagree.htm	Edgar Link	pending
exhibit1013employmentagree.htm	Edgar Link	pending
exhibit1014employmentagree.htm	Edgar Link	pending
exhibit1015employmentagree.htm	Edgar Link	pending
exhibit1016employmentagree.htm	Edgar Link	pending
exhibit1017employmentagree.htm	Edgar Link	pending
exhibit1018employmentagree.htm	Edgar Link	pending
exhibit1019separationagree.htm	Edgar Link	pending
exhibit101indemnityagreeme.htm	Edgar Link	pending
exhibit1020_formofinduceme.htm	Edgar Link	pending
exhibit105lonzaagreement.htm	Edgar Link	pending
exhibit106marylandlease.htm	Edgar Link	pending
exhibit107victoriapressbui.htm	Edgar Link	pending
exhibit108existingvictoria.htm	Edgar Link	pending
exhibit109_catalentsupplya.htm	Edgar Link	pending
exhibit211listofsubsidiari.htm	Edgar Link	pending
exhibit231consentofindepen.htm	Edgar Link	pending
exhibit311certification302.htm	Edgar Link	pending
exhibit31articlesofamalgam.htm	Edgar Link	pending
exhibit321certificationsox.htm	Edgar Link	pending
exhibit41formofcommonshare.htm	Edgar Link	pending
exhibit43descriptionofcomm.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
image_11.jpg	Edgar Link	pending
image_21.jpg	Edgar Link	pending
image_31.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pwcconsentfor10-k1a.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2020 Q4 Form 10-K Financial Statement

#000162828021003060 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2020 Q4 Form 10-K Financial Statement

#000162828021003060 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph